journal
https://read.qxmd.com/read/38507187/characteristics-and-6-month-outcomes-in-patients-with-rheumatoid-arthritis-initiating-infliximab-biosimilar-ifx-dyyb-in-a-real-world-setting
#1
JOURNAL ARTICLE
Joshua F Baker, Catherine Bakewell, Ara Dikranian, Gordon Lam, Jacqueline O'Brien, Page C Moore, Miao Yu, Peter Hur, Karim R Masri
INTRODUCTION: Real-world studies describing biosimilar initiation or switching in patients with rheumatoid arthritis (RA) are limited. The aim of this study was to assess treatment patterns and effectiveness of real-world patients with RA initiating infliximab biosimilar IFX-dyyb (CT-P13; Inflectra® ) in the USA. METHODS: This observational study evaluated patients with RA from the CorEvitas RA Registry who initiated IFX-dyyb and had Clinical Disease Activity Index (CDAI) recorded at baseline and 6 months...
March 20, 2024: Rheumatology and Therapy
https://read.qxmd.com/read/38498142/long-term-efficacy-following-intra-articular-injection-of-carboxymethyl-chitosan-a-new-product-class-for-knee-osteoarthritis-results-from-an-observational-study-in-germany
#2
JOURNAL ARTICLE
Nils A Lynen, Christoph Eichhorn, Nicolas Portelange, Mickaël Chausson, Wim Weyenberg
INTRODUCTION: Evaluate the real-world efficacy of a single intra-articular injection of carboxymethyl-chitosan (CM-chitosan), a new product class for knee osteoarthritis (OA). METHODS: This post-marketing study included adult patients with knee OA, who received a single injection of 60 mg CM-chitosan (currently marketed as KioMedinevs one) according to the instructions for use. Follow-up was performed at weeks 1, 12, 24, and 36. Efficacy was evaluated using a Visual Analog Scale (VAS) score for pain, the Knee injury and Osteoarthritis Outcome Score (KOOS), Patient's Global Assessment (PGA), and overall patient satisfaction...
March 18, 2024: Rheumatology and Therapy
https://read.qxmd.com/read/38498141/efficacy-and-safety-of-risankizumab-for-active-psoriatic-arthritis-100-week-results-from-the-phase%C3%A2-3-keepsake%C3%A2-1-randomized-clinical-trial
#3
JOURNAL ARTICLE
Lars Erik Kristensen, Mauro Keiserman, Kim Papp, Leslie McCasland, Douglas White, Kyle Carter, Ralph Lippe, Huzefa Photowala, Leonidas Drogaris, Ahmed M Soliman, Michael Chen, Byron Padilla, Frank Behrens
INTRODUCTION: Patients with psoriatic arthritis (PsA) require treatment providing durable long-term efficacy in different disease domains as well as safety. We present 100-week efficacy and safety results of risankizumab in patients with active PsA and previous inadequate response/intolerance to ≥ 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR). METHODS: KEEPsAKE 1 (NCT03675308) is a global phase 3 study, including a 24-week, double-blind, placebo-controlled and ongoing open-label extension periods...
March 18, 2024: Rheumatology and Therapy
https://read.qxmd.com/read/38498140/long-term-efficacy-and-safety-following-switch-between-upadacitinib-and-adalimumab-in-patients-with-rheumatoid-arthritis-5-year-data-from-select-compare
#4
JOURNAL ARTICLE
Roy Fleischmann, Ricardo Blanco, Filip Van den Bosch, Louis Bessette, Yanna Song, Sara K Penn, Erin McDearmon-Blondell, Nasser Khan, Kelly Chan, Eduardo Mysler
INTRODUCTION: This study aimed to describe the long-term efficacy and safety of upadacitinib and adalimumab through 228 weeks following immediate switch to the alternate therapy with a different mechanism of action (MoA) in patients with rheumatoid arthritis (RA) not achieving treatment goals with their initial randomized therapy in the ongoing phase 3 SELECT-COMPARE study. METHODS: Patients with non-response or incomplete response to initially prescribed upadacitinib 15 mg once daily or adalimumab 40 mg every other week were switched to the alternate therapy by week 26...
March 18, 2024: Rheumatology and Therapy
https://read.qxmd.com/read/38498139/efficacy-and-safety-of-risankizumab-for-active-psoriatic-arthritis-100-week-results-from-the-keepsake%C3%A2-2-randomized-clinical-trial
#5
JOURNAL ARTICLE
Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M Chen, Byron Padilla, Alan Kivitz
INTRODUCTION: Long-term therapeutic options providing durable response and tolerability are needed for psoriatic arthritis (PsA). The ongoing KEEPsAKE 2 trial is evaluating risankizumab treatment in patients with active PsA who previously had inadequate response/intolerance to ≥ 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR) and/or 1-2 biologic DMARDs (bDMARD-IR). Herein, we report results through 100 weeks of treatment. METHODS: KEEPsAKE 2 is a global phase 3 trial...
March 18, 2024: Rheumatology and Therapy
https://read.qxmd.com/read/38488976/long-term-etanercept-response-for-patients-with-radiographic-axial-spondyloarthritis-based-on-achievement-of-early-intermediate-or-late-responses-during-index-studies
#6
JOURNAL ARTICLE
Xenofon Baraliakos, Annette E Szumski, Kenneth K Kwok, Bonnie Vlahos, Cecilia E Borlenghi
INTRODUCTION: Short-term placebo (PBO)- or active-controlled clinical studies have demonstrated that etanercept (ETN) is effective and well tolerated in patients with radiographic axial spondyloarthritis (r-axSpA) with long-term efficacy and safety continuing for up to 7 years after treatment start. Short-term randomized controlled trials (RCTs) have shown the efficacy of ETN after 12-24 weeks, with statistically significant improvements as early as week 2. This post hoc analysis investigated the timeframe (i...
March 15, 2024: Rheumatology and Therapy
https://read.qxmd.com/read/38488975/comparative-effectiveness-of-bimekizumab-and-guselkumab-in-patients-with-psoriatic-arthritis-at-52%C3%A2-weeks-assessed-using-a-matching-adjusted-indirect-comparison
#7
JOURNAL ARTICLE
Richard B Warren, Iain B McInnes, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Philip J Mease
INTRODUCTION: Matching-adjusted indirect comparisons (MAIC) were used to assess the relative efficacy of bimekizumab 160 mg every 4 weeks (Q4W) compared to guselkumab 100 mg Q4W or every 8 weeks (Q8W) at 48/52 weeks in patients with psoriatic arthritis (PsA) who were biologic disease-modifying antirheumatic drug-naïve (bDMARD-naïve) or with previous inadequate response or intolerance to tumor necrosis factor inhibitors (TNFi-IR). METHODS: Relevant trials were identified as part of a systematic literature review...
March 15, 2024: Rheumatology and Therapy
https://read.qxmd.com/read/38467912/real-world-effectiveness-of-upadacitinib-for-treatment-of-rheumatoid-arthritis-in-canadian-patients-interim-results-from-the-prospective-observational-close-up-study
#8
JOURNAL ARTICLE
Louis Bessette, Jonathan Chan, Andrew Chow, Larissa Lisnevskaia, Nicolas Richard, Pierre-Andre Fournier, Dalinda Liazoghli, Tanya Girard, Derek Haaland
INTRODUCTION: Upadacitinib (UPA), a selective, reversible, oral Janus kinase (JAK)-1 inhibitor, was approved in 2019 in Canada for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). This phase 4 prospective study aimed to characterise the effectiveness of UPA in the real-world population of patients with RA. METHODS: Adults with RA who initiated treatment with once daily UPA (15 mg) and enrolled in the Canadian Real-Life post-marketing Observational Study assessing the Effectiveness of UPadacitinib for treating rheumatoid arthritis (CLOSE-UP) and who completed a 6-month assessment as of 28 February 2023 were included...
March 11, 2024: Rheumatology and Therapy
https://read.qxmd.com/read/38446398/assessment-of-patient-physician-interactions-in-psoriatic-arthritis-national-results-of-the-assist-study
#9
JOURNAL ARTICLE
Fabio Massimo Perrotta, Rossana Scrivo, Salvatore D'Angelo, Silvia Scriffignano, Andrea Delle Sedie, Laura Coates, Ennio Lubrano
INTRODUCTION: An overarching principle for the management of psoriatic arthritis (PsA) is a shared decision-making process between physicians and patients. The aim of this study is to assess the patient-physician relationship in a group of patients with PsA, by using the Perceived Efficacy in Patient-Physician Interactions (PEPPI) and CollaboRATE instruments. METHODS: This is a cross-sectional multicenter study where consecutive patients with PsA were enrolled. For each patient, the main demographic, comorbid conditions, and clinical data were collected, including the assessment of disease activity, function, quality of life, and impact of disease...
March 6, 2024: Rheumatology and Therapy
https://read.qxmd.com/read/38446397/comparative-effectiveness-of-bimekizumab-and-secukinumab-in-patients-with-psoriatic-arthritis-at-52%C3%A2-weeks-using-a-matching-adjusted-indirect-comparison
#10
JOURNAL ARTICLE
Philip J Mease, Richard B Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Iain B McInnes
INTRODUCTION: Matching-adjusted indirect comparisons (MAICs) were used to compare the efficacy of bimekizumab and secukinumab 150 mg and 300 mg at 52 weeks for the treatment of psoriatic arthritis (PsA) in patients who were biologic disease-modifying anti-rheumatic drug-naïve (bDMARD-naïve) or with previous inadequate response or intolerance to tumor necrosis factor inhibitors (TNFi-IR). METHODS: Relevant trials were systematically identified...
March 6, 2024: Rheumatology and Therapy
https://read.qxmd.com/read/38436916/treatment-persistence-and-switching-patterns-of-adalimumab-biosimilar-abp-501-in-european-patients-with-rheumatologic-diseases
#11
JOURNAL ARTICLE
Ran Jin, Silvia Kruppert, Florian Scholz, Isabelle Bardoulat, Khalil Karzazi, Francois Morand, Greg Kricorian, David Collier, Jonathan Kay
INTRODUCTION: ABP 501 was an adalimumab (ADA) biosimilar approved for treating immune-mediated inflammatory diseases (IMIDs) including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). In this retrospective study, we aimed to examine the treatment patterns of ABP 501 among patients with these IMIDs using German and French pharmacy claims databases. METHODS: Patients with RA, PsA, or AS who initiated ABP 501 between October 2018 and March 2020 and were observed continuously for ≥ 365 days both before and after ABP 501 initiation were included...
March 4, 2024: Rheumatology and Therapy
https://read.qxmd.com/read/38436915/the-evaluation-of-effectiveness-and-safety-of-guselkumab-in-patients-with-psoriatic-arthritis-in-a-prospective-multicentre-real-life-cohort-study
#12
JOURNAL ARTICLE
Piero Ruscitti, Giulia Cataldi, Martina Gentile, Alice Dionisi, Paola Volpe, Annacarla Finucci, Lucrezia Verardi, Claudia Di Muzio, Noemi Italiano, Eleonora Celletti, Myriam Di Penta, Ilenia Di Cola, Alessandra Marrelli, Alessia Alfonsi, Francesco Delle Monache, Francesco Cipollone, Marco Gabini, Paola Cipriani
INTRODUCTION: Guselkumab is an interleukin-23 (IL-23) inhibitor licensed for the treatment of psoriatic arthritis (PsA). This study aimed to evaluate the 6-month effectiveness of guselkumab in patients with PsA in a "real-life" multicentre patient cohort. We also estimated the drug retention rate (DRR) of gusulkumab, also assessing the impact of comorbidities and patient clinical characteristics, in a collective 18-month prospective follow-up. METHODS: Between December 2021 and September 2023, consecutive patients with PsA were evaluated if treated at least for 6 months with guselkumab in a prospective multicentre study to evaluate the effectiveness of the drug by means of disease activity index for psoriatic arthritis (DAPSA) and cumulative DRR...
March 4, 2024: Rheumatology and Therapy
https://read.qxmd.com/read/38430455/neutrophilic-activity-biomarkers-plasma-neutrophil-extracellular-traps-and-calprotectin-in-established-patients-with-rheumatoid-arthritis-receiving-biological-or-jak-inhibitors-a-clinical-and-ultrasonographic-study
#13
JOURNAL ARTICLE
Beatriz Frade-Sosa, Andrés Ponce, Estíbaliz Ruiz-Ortiz, Noemí De Moner, María J Gómara, Ana Belén Azuaga, Juan C Sarmiento-Monroy, Rosa Morlà, Virginia Ruiz-Esquide, Laura Macías, Nuria Sapena, Lola Tobalina, Julio Ramirez, Juan D Cañete, Jordi Yague, Josep M Auge, José A Gomez-Puerta, Odette Viñas, Isabel Haro, Raimon Sanmarti
INTRODUCTION: This study assesses the accuracy of neutrophil activation markers, including neutrophil extracellular traps (NETs) and calprotectin, as biomarkers of disease activity in patients with established rheumatoid arthritis (RA). We also analyse the relationship between NETs and various types of therapies as well as their association with autoimmunity. METHODS: Observational cross-sectional study of patients with RA receiving treatment with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors (JAK-inhibitors) for at least 3 months...
March 2, 2024: Rheumatology and Therapy
https://read.qxmd.com/read/38416392/comparing-efficacy-of-guselkumab-versus-ustekinumab-in-patients-with-psoriatic-arthritis-an-adjusted-comparison-using-individual-patient-data-from-the-discover-and-psummit-trials
#14
JOURNAL ARTICLE
Pushpike Thilakarathne, Agata Schubert, Steve Peterson, Wim Noel, Barkha P Patel, Fareen Hassan
INTRODUCTION: Two biologic therapies for psoriatic arthritis (PsA), guselkumab and ustekinumab, have demonstrated superior efficacy versus placebo in clinical trials. However, no head-to-head studies have been conducted comparing these two treatments for PsA. The objective was to indirectly compare guselkumab and ustekinumab on joint and skin efficacy up to week 52, using pooled individual patient-level data (IPD) from PsA trials. METHODS: IPD, including baseline characteristics, American College of Rheumatology (ACR) scores and Psoriasis Area Severity Index (PASI) response from guselkumab (DISCOVER-1 and -2) and ustekinumab (PSUMMIT 1 and 2) trials were pooled...
February 28, 2024: Rheumatology and Therapy
https://read.qxmd.com/read/38416391/use-of-apremilast-to-achieve-psoriatic-arthritis-treatment-goals-and-satisfaction-at-1-year-in-the-canadian-real-world-appraise-study
#15
JOURNAL ARTICLE
Vinod Chandran, Louis Bessette, Carter Thorne, Maqbool Sheriff, Proton Rahman, Dafna D Gladman, Sabeen Anwar, Jennifer Jelley, Anne-Julie Gaudreau, Manprit Chohan, John S Sampalis
INTRODUCTION: The APPRAISE study was conducted to better understand the 12-month effectiveness, tolerability, and patient satisfaction with apremilast treatment for patients with psoriatic arthritis (PsA) in real-world settings. METHODS: APPRAISE (NCT03608657), a prospective, multicenter, observational study, enrolled adults with active PsA prescribed apremilast per routine care between July 2018 and March 2020. Patients were followed for 12 months with visits suggested every 4 months...
February 28, 2024: Rheumatology and Therapy
https://read.qxmd.com/read/38386178/work-productivity-and-general-health-through-2-years-of-guselkumab-treatment-in-a-phase-3-randomized-trial-of-patients-with-active-psoriatic-arthritis
#16
JOURNAL ARTICLE
Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P Kollmeier, Natalie J Shiff, Chenglong Han, May Shawi, William Tillett, Philip J Mease
INTRODUCTION: To evaluate the effect of guselkumab on work productivity and nonwork daily activity impairment and general health status through 2 years in patients who were biologic-naïve with active psoriatic arthritis (PsA) in the phase 3 DISCOVER-2 clinical trial. METHODS: Adult patients with PsA were randomized to subcutaneous injections of guselkumab 100 mg every 4 weeks (Q4W); at weeks 0, 4, then every 8 weeks (Q8W); or placebo (through week 24 with crossover to guselkumab Q4W)...
February 22, 2024: Rheumatology and Therapy
https://read.qxmd.com/read/38376734/reproductive-effect-by-rheumatoid-arthritis-and-related-autoantibodies
#17
REVIEW
Ping-Fen Li, Shan Li, Peng-Sheng Zheng
Rheumatoid arthritis (RA) is a common inflammatory arthritis in women. The effects of RA on the reproductive system are usually overlooked, as RA is not diagnosed until later in reproductive age. Whether RA itself or its related rheumatoid antibodies have an impact on female reproductive function has long been a thought-provoking issue. In brief, relevant epidemiological evidence has shown that women affected by RA are more likely to have coexisting reproductive disorders, including infertility, endometriosis, and premature ovarian insufficiency (POI), or to subsequently develop them...
February 20, 2024: Rheumatology and Therapy
https://read.qxmd.com/read/38372857/reliability-exercise-of-ultrasound-salivary-glands-in-sj%C3%A3-gren-s-disease-an-international-web-training-initiative
#18
JOURNAL ARTICLE
Baptiste Quéré, Alain Saraux, Guillermo Carvajal-Alegria, Dewi Guellec, Gaël Mouterde, Christophe Lamotte, Daniel Hammenfors, Malin Jonsson, Sung-Eun Choi, Min Hong-Ki, Alja Stel, Benjamin A Fisher, Mark Maybury, Benedikt Hofauer, Francesco Ferro, Vera Milic, Dana Direnzo, Valérie Devauchelle-Pensec, Sandrine Jousse-Joulin
INTRODUCTION: Major salivary gland ultrasonography (SGUS) demonstrated its good metric properties as an outcome measure for diagnosing primary Sjögren's disease (SD). The objective was to assess SGUS reliability among sonographers with different levels of experience, using web training. METHODS: Sonographers from expert centers participated in the reliability exercise. Before exercises, training was done by videoconferencing. Reliability of the two most experienced sonographers (MES) was assessed and then compared to other sonographers...
February 19, 2024: Rheumatology and Therapy
https://read.qxmd.com/read/38361040/thermography-at-the-elbow-among-patients-with-rheumatoid-arthritis-a-comparison-with-ultrasound-detected-joint-inflammation-findings
#19
JOURNAL ARTICLE
York Kiat Tan, Rehena Sultana, Julian Thumboo
INTRODUCTION: There is a lack of data on the use of thermography for elbow joint inflammation assessment among patients with rheumatoid arthritis (RA). Hence, we aimed to compare thermography with ultrasonography (a more established imaging modality for joint inflammation assessment) in the assessment of inflammation in the elbows of patients with RA. METHODS: Standardised minimum (Tmin), maximum (Tmax) and average (Tavg) temperatures at each elbow (medial, lateral, posterior and anterior aspects) were summed to obtain the thermographic parameters MIN, MAX and AVG, respectively...
February 15, 2024: Rheumatology and Therapy
https://read.qxmd.com/read/38349593/anemia-and-low-body-mass-index-in-axial-spondyloarthritis-results-from-chinaspa-the-chinese-spondyloarthritis-registry
#20
JOURNAL ARTICLE
Hailong Li, Qingyang Li, Xinwang Duan, Shangzhu Zhang, Yanhong Wang, Jian Xu, Qin Li, Lijun Wu, Zhenbiao Wu, Min Yang, Shengyun Liu, Jinmei Su, Mengtao Li, Xiaofeng Zeng, Xiang Gao
INTRODUCTION: Anemia and malnutrition are recognized indicators of suboptimal physical condition in chronic inflammatory diseases. This study aimed to examine the association between anemia, low body mass index (BMI), and clinical outcomes in axial spondyloarthritis (axSpA). METHOD: This cross-sectional analysis utilized data from the multicenter ChinaSpA cohort. A total of 4146 participants with axSpA were categorized into four groups based on BMI and hemoglobin levels: those with both anemia and low BMI, those with anemia only, those with low BMI only, and those with neither condition...
February 13, 2024: Rheumatology and Therapy
journal
journal
53766
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.